A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 402-409

  Weiss, Geoffrey R ^a   Shaffer, Don W ^d,e   DeMoor, Carl ^a   Rinaldi, David A ^c   Rodriguez, Gladys I ^a,b   Eckardt, John R ^a,b   Stephens, Clyde ^b   Von Hoff, Daniel D ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d EISENHOWER ARMY MEDICAL CENTER   (United States)

^e West Paces Medical Center   (United States)

Author keywords

Etoposide; Granulocyte macrophage colony stimulating factor (sargramostim), phase I trial

Indexed keywords

ETOPOSIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 0029903039     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00005     Document Type: Article

References (20)

1. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity of chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22.
2. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-70.
3. Herrmann F, Schultz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancies treated with recombinant granulocyte colony-stimulating factor. J Clin Oncol 1989; 7: 159-167.
4. Phillips N, Jacob S, Stoller R, Earle M, Przepiorka D, Shadduck RK. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in patients with refractory metastatic carcinoma. Blood 1989; 74: 26-34.
5. van Maanen JMS, Retél J, de Vries J, Dinedo HM. Mechanism of action of the antitumor drug etoposide: A review. J Natl Cancer Inst 1988; 80: 1526-1533.
6. Package Insert. Vepesid® (etoposide), Bristol-Myers Squibb, Inc.
7. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374-377.
8. Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol 1989; 7: 396-401.
9. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase I trial. J Clin Oncol 1990; 9: 1613-17.
10. Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990; 26: 818-21.
11. Waits TM, Johnson DH, Hainsworth JD, Hende KR, Thomas M, Greco FA. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992; 10: 292-6.
12. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994; 12: 986-91.
13. Salmon SE, Liu R. Effects of granulocyte-macrophage colony stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 1989; 7: 1346-50.
14. Foulke RS, Marshall MH, Trotta PP, Von Hoff DD. In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264-7.
15. Von Hoff DD. Use of a human tumor cloning system to identify potentially synergistic combinations of biologic and cytotoxic agents. In: Combining biological response modifiers with cytotoxics in the treatment of cancer: developing a rational approach to new therapy. Baltimore: National Cancer Institute Symposium 1990.
16. Shaffer DW, Smith LS, Burris HA, et al. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res 1993; 53: 5929-33.
17. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophase colony-stimulating factor. N Engl J Med 1992; 327: 28-35.
18. Donahue RE, Wang EA, Kaufman RJ, et al. Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. NY Cold Spring Harbor Symp Quant Biol 1986; 51: 685-92.
19. Shadduck RK, Waheed A, Evans C, Snlecki M, Rosenfeld CS. Serum and urinary Jevels of recombinant human granulocyte-macrophage colony-stimulating factor: Assessment after intravenous infusion and subcutaneous injection. Exp Hematol 1990; 18: 601.
20. Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-41.